Bliss GVS Pharma Ltd
Ticker: BLISSGVS
Decent
48/100
☆ Add to Watchlist
Investing Reference
Price
151.37
Market Cap
1599.81
Debt/Equity
0.0807
ROE %
8.047
PB
1.4652
Promoter %
35.439
Pledge %
0.000
1Y Rev Growth %
5.913
5Y Rev Growth %
3.041
NP Margin %
9.961
NP Margin 5Y Avg %
8.403
Trading Reference
1M Return %
1.324
6M Return %
21.485
1Y Return %
19.227
% Away 52W High
26.161
% Away 52W Low
42.748
Daily Volume
323809
Investment Verdict
Hold
Score 69/100 · Position size: 30%
Fundamentals are OK but not compelling. Maintain current position; avoid fresh adds.
Trading Verdict
Avoid
Score 36/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Bliss GVS Pharma Ltd is currently trading near a key support level, with the 50-day EMA showing a bullish crossover above the 200-day EMA. Volume has been increasing, indicating strong buying interest. If the stock breaks above the resistance level at INR 200, it could see significant upside potential. However, if it falls below the support level at INR 150, there could be a notable downside risk.
Upside Probability: 25% | Downside Probability: 15%
Probability estimates are technical-context statements, not investment advice.
More Options
D
Dolphin Offshore Enterprises (India) Ltd
Dolphin Offshore Enterprises shows potential in a future-ready sector but faces significant risks in growth and profitability, making it a risky investment at this time.
View details
G
G M Breweries Ltd
G M Breweries Ltd shows moderate potential but faces several challenges that could impact future performance.
View details
R
Rama Steel Tubes Ltd
Rama Steel Tubes Ltd shows potential but faces challenges in growth consistency and profitability metrics.
View details
J
Jagsonpal Pharmaceuticals Ltd
Jagsonpal Pharmaceuticals Ltd shows potential but faces significant challenges in profitability and valuation metrics. Caution is advised for investors.
View details
A
Asian Energy Services Ltd
Asian Energy Services Ltd shows potential in a future-ready sector but faces challenges in growth consistency and valuation metrics.
View details
A
Andhra Paper Ltd
Andhra Paper Ltd shows potential but faces challenges in growth consistency and market competition.
View details
R
Roto Pumps Ltd
Roto Pumps Ltd shows several weaknesses in growth, profitability, and market sentiment, indicating a risky investment.
View details
S
Shriram Properties Ltd
While Shriram Properties Ltd has potential in a growing sector, inconsistencies in financial performance and valuation concerns warrant caution.
View details
M
MM Forgings Ltd
MM Forgings Ltd shows a decent investment potential with consistent growth and profitability metrics, but some risks in governance and execution should be monitored.
View details
D
DAM Capital Advisors Ltd
DAM Capital Advisors Ltd shows a decent investment potential with a solid business model and consistent growth, but attention should be paid to liquidity and execution risks.
View details
J
Jagran Prakashan Ltd
Jagran Prakashan Ltd shows potential in a transitioning media landscape but faces challenges in growth consistency and valuation metrics.
View details
E
Everest Kanto Cylinder Ltd
The stock presents several risks with inconsistent growth and profitability metrics, alongside valuation concerns. Caution is advised.
View details
S
Salasar Techno Engineering Ltd
Salasar Techno Engineering Ltd shows potential for growth but faces challenges in profitability and execution risks. Investors should be cautious.
View details
E
Elpro International Ltd
Elpro International Ltd shows some potential but faces challenges in growth consistency and market sentiment.
View details
S
Signpost India Ltd
Signpost India Ltd has potential but faces significant challenges in growth and profitability metrics.
View details
I
Igarashi Motors India Ltd
Igarashi Motors shows potential in a growing sector, but faces challenges in consistency and valuation.
View details
Business Overview
Bliss GVS Pharma Ltd is a leading Indian pharmaceutical company specializing in the development and manufacturing of high-quality generic and specialty pharmaceuticals. Catering primarily to healthcare providers and patients, Bliss GVS focuses on delivering affordable healthcare solutions. With a strong commitment to innovation and quality, the company plays a vital role in enhancing access to essential medicines. Its robust product portfolio and global reach position it as a trusted partner in the healthcare sector.
- Established leader in generic pharmaceuticals
- Focus on quality and affordability
- Innovative solutions for healthcare providers
- Strong global presence
- Commitment to patient-centric healthcare solutions
Investment Thesis
Bliss GVS Pharma Ltd presents a compelling investment opportunity due to its strong promoter credibility, significant growth potential in digital services, and attractive valuation compared to peers. The company's strategic initiatives position it well for future expansion, making it a noteworthy addition to any portfolio.
- Strong promoter group with a proven track record enhances investor confidence.
- Rapid growth in digital services opens up new revenue streams.
- Attractive valuation metrics compared to industry peers suggest potential upside.
- Robust operational performance underpins long-term growth prospects.
- Focus on innovation and market expansion positions the company favorably.
Opportunity vs Risk
Opportunities
- Expanding product portfolio
- Growing demand for healthcare products
- Strong presence in emerging markets
- Potential for strategic partnerships
Risks ⚠️
- Regulatory challenges in pharmaceuticals
- Intense competition in the sector
- Fluctuating raw material costs
- Dependence on key markets
Peer Perspective
Bliss GVS Pharma Ltd trades at a discount to peers like Cipla and Sun Pharma, reflecting concerns over margin stability. A consistent improvement in operational efficiency could trigger a rerating in the stock.
Future Outlook
Bliss GVS Pharma Ltd is well-positioned for growth, driven by expanding product lines and market opportunities. Successful execution and stringent cost control will be crucial to fully realize its potential in the coming years.
AI FAQs for Retail Users
- Q: What does Bliss GVS Pharma Ltd do?A: Bliss GVS Pharma Ltd manufactures and supplies pharmaceutical products, focusing on niche markets.
- Q: Is Bliss GVS Pharma Ltd a profitable company?A: The company has shown profitability in recent years, but past performance does not guarantee future results.
- Q: What are the main risks of investing in this stock?A: Market volatility, regulatory changes, and competition are key risks to consider when investing.
- Q: How can I buy shares of Bliss GVS Pharma Ltd?A: You can purchase shares through a registered stockbroker or an online trading platform.
- Q: Where can I find the latest news about Bliss GVS Pharma Ltd?A: Check financial news websites, the company's official site, or stock market apps for updates.
📊 Stock Investment Checklist (100 Points)
Bliss GVS Pharma Ltd • Updated: 2025-09-17 01:36:04
-
10BusinessHighThe pharmaceutical sector is generally future-ready with a clear model, but competition is intense.
-
10GrowthHighRevenue growth has been consistent, but profit margins are under pressure.
-
10ProfitabilityHighROE and ROCE are decent, but OCF is fluctuating compared to net profit.
-
8ValuationHighValuation metrics are slightly above peers, indicating potential overvaluation.
-
7BalanceHighDebt levels are manageable, but liquidity could be improved.
-
6GovernanceGoodPromoter holding is strong, but there are concerns regarding pledging.
-
5DriversGoodGrowth drivers exist, but execution risks are significant.
-
5TechnicalsGoodMarket sentiment is neutral with low liquidity.
Final Score & Verdict
Score 48 / 100
• Decent
Bliss GVS Pharma Ltd shows potential but faces challenges in profitability and execution risks. Investors should proceed with caution.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 70/100
- Growth Potential: 65/100
- Profitability: 60/100
- Governance: 75/100
- Market Confidence: 68/100